PT  - JOURNAL ARTICLE
AU  - Barbosa, Gabriela Rodrigues
AU  - Leão Moreira, Luiz Vinicius
AU  - Oliveira Justo, Alberto Fernando
AU  - Perosa, Ana Helena
AU  - Cunha Chaves, Ana Paula
AU  - Bueno, Mariana Sardinha
AU  - de Souza Luna, Luciano Kleber
AU  - Conte, Danielle Dias
AU  - Almeida Carvalho, Joseane Mayara
AU  - Prates, Janesly
AU  - Dantas, Patricia Sousa
AU  - Faico-Filho, Klinger Soares
AU  - Camargo, Clarice
AU  - Resende, Paola Cristina
AU  - Mendonça Siqueira, Marilda
AU  - Bellei, Nancy
TI  - Rapid spread and high impact of the Variant of Concern P.1 in the largest city of Brazil
AID  - 10.1101/2021.04.10.21255111
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.10.21255111
4099  - http://medrxiv.org/content/early/2021/04/14/2021.04.10.21255111.short
4100  - http://medrxiv.org/content/early/2021/04/14/2021.04.10.21255111.full
AB  - First in Manaus in the Brazilian Northern region, the Variant of Concern P.1 traveled 3800 kilometers southeast to endanger Sao Paulo contributing to the collapse of the health system. Here, we show evidence of how fast the VOC P.1 has spread in the most populated city in South America.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundings to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in compliance with institutional guidelines, approved by the Ethics Committee of Sao Paulo Federal University (CEP/UNIFESP n. 29407720.4.0000.5505).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available in GISAID at https://www.gisaid.org/ reference number EPI_ISL_1464630 to EPI_ISL_1464677.